Last reviewed · How we verify
Shanghai Municipal Center for Disease Control and Prevention — Portfolio Competitive Intelligence Brief
4 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| 1 dose MMR | 1 dose MMR | marketed | ||||
| A second dose with an 3 year interval | A second dose with an 3 year interval | marketed | ||||
| A second dose with an 5 year interval | A second dose with an 5 year interval | marketed | Immunology | |||
| A second dose with an 1 year interval | A second dose with an 1 year interval | marketed | vaccine | Immunology |
Therapeutic area mix
- Immunology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Aduro Biotech, Inc. · 1 shared drug class
- Aeras · 1 shared drug class
- Aga Khan University · 1 shared drug class
- Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · 1 shared drug class
- Alba Maria Ropero · 1 shared drug class
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
- Asoc. Prof. Erdoğan Selçuk Şeber · 1 shared drug class
- ANRS, Emerging Infectious Diseases · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Shanghai Municipal Center for Disease Control and Prevention:
- Shanghai Municipal Center for Disease Control and Prevention pipeline updates — RSS
- Shanghai Municipal Center for Disease Control and Prevention pipeline updates — Atom
- Shanghai Municipal Center for Disease Control and Prevention pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Shanghai Municipal Center for Disease Control and Prevention — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-municipal-center-for-disease-control-and-prevention. Accessed 2026-05-17.